Reference List

Notes: Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo
Abstract: A cell line designated RMG-II was established from the ascites of a patient with ovarian clear cell carcinoma. The chromosomal analysis revealed aneuploidy with a hypertetraploid modal number and 8 marker chromosomes. Radioimmunoassay and immunocytochemical staining showed that RMG-II cells produced some tumor markers such as CA125 and TPA. Two monoclonal antibodies, designated MA602-1 and MA602-6, were generated by immunization of mice with an extract prepared from the culture supernatant of RMG-II cells. The epitopes recognized by these two monoclonal antibodies were proved to differ from the CA125 epitope, but to exist on the molecule bearing CA125. We developed a double-determinant sandwich enzyme immunoassay using these two monoclonal antibodies, and the antigen defined by this assay was termed CA602. CA602 was frequently found in the sera of ovarian cancer patients; the positive rates were 92%, 38%, 60%, and 80% for serous, mucinous, clear cell, and endometrioid ovarian carcinomas, respectively, when the cut-off value was set at 60 U/ml (= mean + 3SD of healthy females). CA602 levels in serum were also high in endometriosis patients and in early pregnancy, as is the case for CA125, and the correlation coefficient between CA602 and CA125 was high (r = 0.88). Our preliminary evidence suggests that this CA602 assay system has higher sensitivity than the CA125 one
Reference ID: 5250

Notes: Dept of Obstetrics and Gynecology, Keio University School of Medicine
Abstract: Since cultured cells have the possibility to produce tumor-associated substances in vitro, we generated several monoclonal antibodies using cultured cells as immunogen and applied them to cancer diagnosis. Two monoclonal antibodies (F602-1 and F602-6) were generated against a newly established ovarian mesonephroid cancer cell line (RMG-II), and a double determinants sandwich enzyme-immunoassay system was developed. Their epitopes were proved to exist on the CA125 molecules, but to be different from the one recognized by OC125, and almost the same result of serum assay as CA125 was obtained by this assay. A new monoclonal antibody (MSN-1) was produced by immunizing a new endometrial cancer cell line (SNG-II). MSN-1 recognized the Lewis-b carbohydrate moiety on the cell surface glycolipid, and seldom reacted immunohistochemically with normal endometrium, but reacted with about 90% of endometrial cancer cases. By application of MSN-1 to flow-cytometry, the possibility of differentiating endometrial normal cells from the cancer cells was demonstrated (Manuscript in Japanese).
Reference ID: 5251